# Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

> **NCT01685216** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 7 (actual)

## Conditions studied

- Gaucher Disease, Type 3

## Interventions

- **BIOLOGICAL:** velaglucerase alfa

## Key facts

- **NCT ID:** NCT01685216
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-14
- **Primary completion:** 2015-03-15
- **Final completion:** 2015-03-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685216, "Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01685216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*